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There is ample evidence that the acute stress response is altered in schizophrenia and bipolar
disorder. However, it is not clear whether such changes are related to the illness, a genetic
vulnerability, or is the result of medication that is used in the majority of these patients. Therefore,
we investigated determinants of the acute endocrine and autonomic stress response in healthy
controls (n=48), euthymic BD1 patients (n=49) and unaffected siblings of BD1 patients (n=27). All
participants completed a validated psychosocial stress task, the Trier Social Stress Test for Groups
(TSST-G). Saliva levels of alpha-amylase and cortisol were measured before, during, and after
exposure to stress. Compared to controls, we found a signiﬁcantly blunted cortisol stress response
in BD1 patients. Conversely, BD1 patients displayed exaggerated alpha-amylase levels in response
to stress. Antipsychotic use was a signiﬁcant contributing factor to the blunted cortisol stress
response in BD1 patients. Unaffected BD1 siblings displayed similar stress-induced cortisol and
alpha-amylase levels as controls, suggesting that familial risk for BD1 did not have a large effect on
the functionality of the stress system. In conclusion, this study shows that euthymic BD1 patients
have a substantially blunted endocrine stress response but an exaggerated autonomic stress
response and that the endocrine stress response differences can be largely contributed to
antipsychotic use rather than constitute a speciﬁc BD1 phenotype or vulnerability.
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L.C. Houtepen et al.781. Introduction patient associations. Siblings (n=27) were not related to BD1In psychiatric disorders such as schizophrenia, bipolar dis-
order and major depressive disorder, blunted and increased
stress responsivity have been reported (Brenner et al.,
2009; Petrowski et al., 2013; Lange et al., 2013). However,
our understanding of the neurobiological background alte-
red stress response in these disorders is limited. There are
indications in BD1 patients that stress exposure results in a
blunted endocrine stress response (Wieck et al., 2013) and
reduced heart rate variability (Cohen et al., 2003). BD1
patients also display an increased basal activity of the
endocrine and autonomic systems as reﬂected by an
increased cortisol awakening response (Cervantes et al.,
2001) and increased basal sympathetic nervous system (SNS)
activity (Lake et al., 1982). Even though there are indica-
tions that stress system functionality is altered in BD1, it is
currently unknown whether stress reactivity is consistently
altered in BD1 patients and which factors may inﬂuence
stress reactivity.
In other psychiatric populations, several factors have
been identiﬁed that inﬂuence stress reactivity, including
childhood maltreatment (Heim et al., 2000), and the
number of depressive episodes (Morris et al., 2012). Inves-
tigating the inﬂuence of psychiatric medication such as
antidepressants (Lange et al., 2013) and antipsychotics
(Cohrs et al., 2006) is also relevant as these drugs can alter
HPA axis activity. Moreover, multiple studies in healthy
controls have clearly linked genetic markers to altered
stress reactivity in the TSST task (see for example (van
Leeuwen et al., 2011; DeRijk and de Kloet, 2008)). In light
of the high heritability of BD1 and alterations in the stress
system, impaired stress system functionality in BD1 may also
be the result of a genetic predisposition for BD1 (Ising and
Holsboer, 2006). If a genetic BD1 predisposition would result
in altered stress reactivity, it is expected that unaffected
adult siblings of BD1 patients, who on average share 50% of
risk genes with probands, display a similar altered stress
response.
This study aims to establish i) indices for both HPA-axis
and ANS reactivity to stress in euthymic BD1 patients and
ii) examine to what extent disease characteristics, medica-
tion, and genetic vulnerability contribute to aberrant stress
reactivity of BD1 patients. To this end, we exposed euthy-
mic BD1 patients to a group-wise Trier Social Stress Test
(TSST-G), and compared this group to unrelated unaffected
healthy siblings of BD1 patients and healthy controls.2. Experimental procedures
2.1. Participants
Participants were eligible for participation if they had 3 or more
Dutch grandparents and were ﬂuent in Dutch, in view of the verbal
test. Participants were instructed to refrain from heavy meals, drinks
other than water and heavy exercise at least 2 h before the stress
task, as well as to refrain from caffeine use at least 4 h before the
experimental session. All participants reported that they had adhered
to these instructions. Participants had not previously been enrolled
in stress-related research and were unfamiliar with each other.
Between December 2011 and June 2013, participants were recruited
through ﬂyers at general hospitals, psychiatric institutions, andparticipants (n=49). Healthy controls (n=48) were matched based
on age and gender. The study was approved by the Utrecht Medical
Center ethical review board and performed according to the ICH
guidelines for Good Clinical Practice and the Declaration of Helsinki
and its latest amendments. All participants gave their written
informed consent prior to their inclusion in the study and were
ﬁnancially compensated.
2.2. Clinical characteristics and drug use
On the day of testing lifetime DSM-IV diagnoses in unaffected
siblings and healthy controls group were assessed with the Mini
International Neuropsychiatric Interview (MINI) plus (Sheehan
et al., 1998). For all BD1 participants clinical characteristics
including BD1 diagnosis, comorbid psychiatric diagnosis, number
of manic and depressed episodes, and age of disease onset were
established with the Structured Clinical Interview for DSM-IV (SCID)
(First et al., 2002). The interviews were conducted by at least one
well-trained independent rater.
Just before the experiments euthymic mood status in BD1 patients
was conﬁrmed using the 30-item Inventory of Depressive Symptoma-
tology (IDS-C30, range 0–24 (Rush et al., 1996)) and Young Mania Rating
Scales (YMRS, range 0–7 (Tohen et al., 2000; Young et al., 1978))
interviews. Participation was postponed if participants scored above
predeﬁned cut off values on the YMRS (above 12) or IDS-C30 (above
24). Based on these criteria, 2 participants were rescheduled for a
different test day.
Current use of psychoactive substances (amphetamines, MDMA,
barbiturates, cannabinoids, benzodiazepines, cocaine, and opiates)
was determined with a urine multi-drug screening device (InstantView)
and self-report questionnaire. All participants reporting psychiatric
medication use (antidepressants, benzodiazepines, anticonvulsants
and antipsychotics), were on a stable (at least one month) dosing
schedule. Benzodiazepine use was conﬁrmed by the urine screen. The
dose of antipsychotics was transformed to chlorpromazine (CPZ)
equivalents as previously described (Woods, 2003).If participants
smoked daily, they were deﬁned as a smoker. Furthermore, female
participants were explicitly asked for information about their men-
strual cycle and contraceptive medication use as this can inﬂuence
HPA axis activity (Kirschbaum et al., 1999).
Four participants (3 controls and 1 BD1 patient) scored positive
for cannabis use. Exclusion of the cannabis users did not change any
of the results. Four participants (3 BD1 patients and 1 sibling of BD1
patient) taking beta blockers for high blood pressure were excluded
from alpha-amylase analysis as its use impairs the alpha-amylase
response (van Stegeren et al., 2006). Since beta blocker use does
not affect the cortisol stress response (Kudielka et al., 2007),
participants (N=4) taking beta blockers were included for cortisol
analysis. Nevertheless, exclusion of these participants did not
change any of the cortisol results.2.3. Procedures
2.3.1. General
Participants were tested between 1300 h and 1700 h to control for
diurnal variations of cortisol secretion. Participants completed an
individual assessment of current mood and symptomology based on
psychiatric diagnostic interviews (see paragraph Clinical character-
istics and drug use). Participants were instructed not to commu-
nicate with each other before being escorted to a waiting area. Ten
minutes prior to the TSST-G, participants received instructions and
subsequently completed the (TSST-G) task as previously described
(Vinkers et al., 2013). In short, participants were instructed to carry
out a public speaking test and subsequently perform an arrhythmic
task. All participants were called upon in random order.
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Saliva was collected using salivettes (Sarstedt, Nümbrecht, Germany)
for analysis of cortisol and alpha-amylase levels. In total, eight saliva
samples were collected in each subject over a 90 min time period
(Fig. 1). Samples were directly stored at 80 1C and analyzed as
previously described (Vinkers et al., 2013). In short, cortisol was
measured without extraction using an in house competitive radio-
immunoassay, and alpha-amylase was measured using a Beckman-
Coulter AU5811 chemistry analyzer. If one (out of 8) saliva samples was
missing, the missing value was obtained by averaging the surrounding
data points. This procedure was used for ten participants (4 controls,
2 siblings and 4 BD1 patients). Exclusion of these 10 participants
altogether from the analyses did not alter any of the results. Three
participants (2 controls and 1 BD1 patient) were excluded because
more than one of the eight salivettes did not contain enough saliva for
analysis.
2.4. Questionnaires
Perceived levels of stress and anxiety were repeatedly assessed at
baseline (t=10 min) and during the stress test (t=+8 min) using
visual analog scales (VAS, 118 mm scale) (Figure 1). Moreover,
previous exposure to traumatic stress inﬂuences stress reactivity
(Carpenter et al., 2007; Heim et al., 2000; Lovallo et al., 2012),
therefore exposure to childhood maltreatment (Childhood Trauma
Questionnaire (CTQ) (Bernstein et al., 2003) and major life events
(Lifetime Stressor Checklist-Revised (LSC-R) (Wolfe et al., (1996)) the
Dutch version as previously used (Vinkers et al., 2014)) were
investigated with questionnaires in all participants.
2.5. Statistical analyses
All statistics were carried out using SPSS version 20 (SPSS Inc.,
Chicago, IL, USA). One way ANOVAs were used to analyze differ-
ences in baseline parameters between groups. When applicable,
Bonferroni post-hoc analysis was performed. If the assumption of
homogeneity of variance was violated, Welch's F test was performed
followed up with a Games-Howell post-hoc analysis (indicated by
non-integerF values). In the case of signiﬁcant baseline differences
in childhood maltreatment, major life events, menopausal status,
contraceptive medication use, cannabis use or smoking status, main
analyses were performed both with and without these indicators as
covariate. Changes in subjective stress rating (VAS during the stress
task – VAS baseline) were analyzed using a one way ANOVA with
group (control, sibling or BD1) as between-subject factor. Cortisol
and alpha-amylase levels were analyzed using repeated measuresFigure 1 The cortisol response to the TSST-G in BD1 patients,
unaffected siblings, and healthy controls. n: po0.05; #: po0.10.ANOVA with group (control/sibling/BD1) and sex as between-subject
factor and age as a covariate. Sex and age were included in the
model as both parameters have been reported to inﬂuence cortisol
and alpha-amylase levels (Nater et al., 2013). Planned follow up
analysis consisted of comparing BD1 patients to controls and BD1
patients to siblings. Results were corrected by the more stringent
Greenhouse–Geisser procedure where appropriate (indicated by an
ε value). If there was a signiﬁcant effect in the repeated measures
analysis, data were analyzed per time point using a one-way ANOVA
with group (control, sibling or BD1) as between-subject factor.
Furthermore in a stratiﬁed analysis of the BD1 group, medication
use and clinical characteristics (age of onset, number of manic and
depressed episodes and comorbid psychiatric diagnosis) were added
as covariates to the repeated measure model. For medication use,
lithium (dose in mgs), antidepressant use (yes/no), benzodiazepine
use (yes/no), anticonvulsant use (yes/no), and antipsychotic use
(yes/no) were used as separate indicators in a single model.
Pearson's correlations were used to investigate the relation
between medication use and clinical characteristics. If there was
a signiﬁcant correlation between a clinical characteristic and
medication use, these measures were both included in the repeated
measures model. The signiﬁcance level was set at Po0.05. All
results are presented as average and standard error of the mean.3. Results
3.1. Lifetime psychiatric disorders and current
mood status
Four healthy controls met criteria for a lifetime but not
current psychiatric disorder and had recovered completely
without professional help: alcohol/drug abuse (n=3) and
agoraphobia (n=1). Exclusion of these four participants
with a history of a psychiatric disorder did not alter any of
the results (data not shown). A total of nine siblings met
criteria for a previous depressive episode, of which 5 experi-
enced recurrent depressive episodes (and 4 of these 5 parti-
cipants used antidepressants at the time of participation).
Three of the siblings who met the criteria for a previous
depressive disorder, also had a comorbid anxiety (n=2) or
alcohol abuse (n=1) diagnosis.
The BD1 diagnosis was conﬁrmed in all recruited BD1
patients. On the experimental day, current mood in the BD1
patients was euthymic as determined by the YMRS (average
1.2, range 0–7) and IDS-C30 (average 5.3, range 0–24). Other
clinical characteristics collected in the BD1 sample were:
number of episodes (average 6.4, range 1–25), age of onset
(average 26.6, range 7–60) and comorbid disorders. Nine
patients (18%) had either a comorbid anxiety (n=7) or
obsessive compulsive (n=2) disorder.3.2. Baseline characteristics
Age, sex, contraceptive use and cannabis use did not signiﬁ-
cantly differ between controls and BD1 patients. The BD1
siblings group contained signiﬁcantly more females, had a
higher average age, and a lower number of smokers compared
to the other groups (Table 1). Inclusion of smoking status
(all p-values 40.12), menopausal status (all p-values 40.16)
or contraceptive use (all p-values 40.20) as covariate had no
effect on either cortisol or alpha-amylase levels and were not
included as a covariate in further analyses.
L.C. Houtepen et al.803.3. Childhood trauma and major life events
Siblings and BD1 patients reported more stressful life events
compared to controls (LSC-R effect F2, 123=7.4 p=0.001;
post-hoc: BD1-control p=0.004 and sibling-control p=0.005).
In contrast, childhood trauma levels were comparable across
all groups (CTQ effect F2, 123=1.3 p=0.27). Inclusion of LSC-R
as covariate had no effect on any signiﬁcance level in the
current study and was not included in subsequent analyses.3.4. Perceived stress levels
Basal subjective stress ratings were comparable between
healthy controls (mean 1.7472.3), siblings of BD1 patients
(mean 1.7671.9), and BD1 patients (mean 2.3672.4)
(F2,123=1.014 p=0.37). Moreover, in response to stress,
there was a similar increase in subjective stress levels
across all groups (F2, 121=1.2 p=0.292).3.5. Cortisol
Groups differed in the endocrine stress response (group effect
F2, 116=6.2 p=0.003; time x group interaction F14, 742=3.2
p=0.010 ε=0.317; see Fig. 2). Planned follow up analysis
revealed that this difference resulted from a signiﬁcantly
blunted cortisol responses in BD1 patients (BD1-control time x
group F7, 588=4.6 p=0.008 ε=0.324). Post-hoc analysis con-
ﬁrmed signiﬁcant different cortisol levels between BD1
patients and controls from 20 min after TSST-G until the end
of measurement (t=90 min) (po0.05). Siblings showed a
similar cortisol stress response as healthy controls (Sibling-
control: time x group F7, 476=2.2 p=0.111; ε=0.298). As
expected, women exhibited an overall blunted cortisol stress
response compared to men (sex effect F1, 116=9.6 p=0.002;
time x sex interaction F7, 472=3.7 p=0.021 ε=0.317). A similarTable 1 Sample characteristics.
Cont
Sex (% female) 52%
Age (years, range) 43.5
Childhood maltreatment (CTQ total score, range) 33.4
Major life events (LSC-R total score, range) 3.90
Cannabis use (yes/no, %) 3 (6.
Smoker(yes/no, %) 11 (2
Contraceptive use (yes/no, %) 5 (20
Lithium (yes/no, %) –
Antipsychotics (yes/no, %) –
Antidepressants (yes/no, %) 1 (2.
Benzodiazepines (yes/no, %) –
Anticonvulsants (yes/no, %) –
Age of onset (years, range) –
Episodes (number, range) –
YMRS score (total score, range) –
IDS-C30 score (total score, range) –
Compared to controls.
n: po0.05.
nn: po0.01.sex effect was found after exclusion of women who used
contraceptives (sex effect F1, 109=9.4 p=0.003; time x sex
interaction F7, 763=3.7 p=0.026 ε=0.302).
3.6. Alpha-amylase
Stress-induced alpha-amylase levels differed between groups
over time (group effect F2, 114=5.7 p=0.004; time x group
interaction F14, 798=3.6 p=0.004 ε=0.353; see Fig. 3). Planned
follow up analysis showed that this difference originated from a
signiﬁcantly increased alpha-amylase response in BD1 patients
(BD1-control time x group interaction F7, 609=7.1 po0.001
ε=0.322). Signiﬁcant differences were present between BD1
patients and healthy controls during all time points (po0.05)
except at t=80 min (p=0.076). In contrast, the alpha-amylase
stress response of siblings was not signiﬁcantly different from
the alpha-amylase stress response in healthy controls (Sibling
vs.-control: time x group interaction F7, 469=1.6 p=0.170
ε=0.452). No signiﬁcant sex effects or interactions were found
(sex effect F1, 114=0.4 p=0.842, time x sex F7, 472=0.2p=0.846
ε=0.353). The alpha-amylase stress response was enhanced in
older participants independent of group status (age effect F1,
114=8.5 p=0.004; time x age F7, 472=2.9 p=0.044 ε=0.353).
3.7. Medication
All BD1 patients used medication, most commonly lithium
(69%) and antipsychotics (61%, average CPZ equivalent
112.8 mg), followed by anticonvulsants (28%), antidepres-
sants (20%), and benzodiazepines (14%).The cortisol stress
response in BD1 patients was not inﬂuenced by use of lithium
(all p-values 40.31), benzodiazepines (all p values40.24),
antidepressants (all p values40.38), or anticonvulsants
(all p values40.295). Similarly, stress-induced alpha-
amylase measures were not inﬂuenced by use of lithium
(all p values 40.16), benzodiazepines (all p values40.08),rol (n=48) Siblings (n=27) BD1 (n=49)
70% 51%
(21–69) 54.5 (32–66) 43.4 (19–67)
(24–63) 34.4 (24–82) 36.9 (24–74)
(0–10) 5.85 (1–11)n 5.61 (0–11)nn
3%) 0 1 (2.0%)
3%) 1 (3.7%)n 18 (36%)
%) 0n 5 (20%)
– 34 (69%)
– 29 (61%)
1%) 4 (15%) 10 (20%)
2 (7.4%) 8 (14%)
– 14 (28%)
– 16.1 (7–60)
– 6.3 (1–25)
– 1.2 (0–7)
– 5.3 (0–24)
Figure 2 The effect of the TSST-G on a-amylase levels in saliva
of BD1 patients, unaffected siblings, and healthy controls.
n: po0.05; #: po0.10.
Figure 3 The effect of antipsychotic use on the cortisol
response to the TSST-G in BD1 patients. The cortisol response
of healthy controls is added for graphical comparison only and
was not used in the statistical model. n: po0.05; #: po0.10.
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p values40.45).
However, antipsychotic use was associated with a blunted
stress-induced cortisol response in BD1 patients (timenantip-
sychotic use F7, 315=4.2 p=0.007 ε=0.369; see Fig. 4). This
antipsychotic effect was speciﬁc for stress-induced cortisol
ﬂuctuations over time since there was no signiﬁcant main
effect of antipsychotic use on overall or basal cortisol levels
in the BD1 group (F1, 45=2.8 p=0.100). Moreover, CPZ equi-
valents showed similar blunted stress-induced cortisol
responses in BD1 patients (timenCPZ F7, 315=5.8 p=0.002
ε=0.350). Antipsychotic use was not signiﬁcantly associated
with either overall or time-dependent levels of stress-
induced alpha-amylase (all p values 40.17). No signiﬁcant
correlations were found between antipsychotic use (CPZ
equivalents) and clinical characteristics (number of episodes
r=0.008 p=0.960; age of onset r=0.038 p=0.813),
therefore clinical characteristics were not used as a covariate
in the analysis of antipsychotics.Figure 4 Number of mood episode (more or less than 5) on the
cortisol stress response in BD1 patients. The cortisol response of
healthy controls is added for graphical comparison only and was
not used in the statistical model. n: po0.05.3.8. Clinical BD1 disease parameters
The number of previous mood episodes was signiﬁcantly
associated with overall decreased cortisol levels in BD1
patients independent of stress exposure (episode effect
F1, 37=6.6, p=0.014; see Figure 4). In contrast, no signiﬁcant
effect of number of previous mood episodes was seen on the
stress-induced cortisol response (time episodes interaction
F7, 259=1.1 p=0.313 ε =0.381). For graphical representation,
number of episodes were divided with a median split in high
(45) and low (r5) number of episodes. Age of onset (all
p values40.26) and comorbid psychiatric diagnosis (all
p values40.19) had no signiﬁcant effect on either cortisol or
alpha amylase levels.4. Discussion
We found that in response to stress, euthymic BD1 patients
perceived similar stress levels as healthy controls but dis-
played a blunted cortisol response and increased alpha-
amylase levels. This blunted cortisol response is in line witha recent study that investigated 13 euthymic female BD1
patients (Wieck et al., 2013). A striking ﬁnding of the current
study is that antipsychotic use was the most important factor
associated with the reduced cortisol stress response in BD1
patients, accounting for most of the differences between
stress-induced cortisol levels in BD1 patients and healthy
controls. After inclusion of antipsychotic use as a covariate,
the blunted cortisol stress response in BD1 patients no longer
signiﬁcantly differed from the one in healthy controls. To our
knowledge, this is the ﬁrst study to show that antipsychotic
use plays an important role in endocrine stress reactivity.
Studies investigating stress reactivity in schizophrenia have
consistently found a blunted cortisol stress response (Jansen
et al., 1998; Jansen et al., 2000; Ritsner et al., 2005), and
antipsychotics have been implicated in this attenuated cortisol
response (Brenner et al., 2009). In support, the majority of
studies found reduced baseline cortisol levels in schizophrenia
patients who used antipsychotics (for review see (Walker
et al., 2008)), and increased cortisol levels are a predictor
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et al., 2005). An advantage of studying the effects of
antipsychotic use in BD1 patients is that – in contrast to
schizophrenia patients - not all patients use antipsychotics.
This enabled the direct comparison of the stress response
between euthymic BD1 patients that use antipsychotics and
those who do not. In our BD1 sample use of antipsychotics was
not correlated to clinical characteristics, such as age of onset
or number of manic and depressed episodes, indicating the
blunted stress induced cortisol response in the antipsychotic
group is not related to these clinical characteristics. Our data
raise the question whether blunted cortisol response in BD1
disorder and schizophrenia may be only the result of anti-
psychotic drug use. This seems unlikely, since a blunted
cortisol response was also present in medication naïve ﬁrst
episode psychotic patients (van Venrooij et al., 2012).
In contrast to the use of antipsychotics, use of lithium,
anticonvulsants, benzodiazepines, and antidepressants did
not signiﬁcantly affect the endocrine and autonomic stress
response in our sample. Even though acute administration of
alprazolam or lamotrigine results in blunted stress-induced
cortisol levels in healthy controls (Fries et al., 2006; Kudielka
et al., 2007; Maheu et al., 2005; Makatsori et al., 2004;
Walker et al., 2008), such effects were not always detected
(Lange et al., 2013; Watson et al., 2004; Roelofs et al., 2009).
The chronic use of psychiatric medication in BD1 patients or
the limited statistical power due to a rather small sample size
may also have contributed to the fact that we found no
signiﬁcant effects for most medication groups in our study.
No signiﬁcant effect was found of either age of onset or
comorbid psychiatric disorders in BD1 patients. Neverthe-
less, an increased number of previous mood episodes was
associated with overall reduced cortisol levels independent
of stress. This adjustment of basal HPA axis activity after an
increasing number of mood episodes is in line with the
kindling hypothesis (Post, 1992), which suggests that during
initial affective episodes, alterations in stress related
systems occur which lead to an increased risk to develop
subsequent mood episodes independent of stressors (for a
recent review of the kindling hypothesis in BD1 see (Bender
and Alloy, 2011)).
Traumatic stress plays an important role in the etiology
and course of BD1 (Proudfoot et al., 2011) and also affects
stress reactivity (Heim et al., 2000; Nater et al., 2007; van
Winkel et al., 2013). Nevertheless, our data do not support
a role for traumatic stress exposure or major life events on
the acute stress response in BD1 patients. First, childhood
maltreatment was similar across the experimental groups
and the number of reported major life events was compar-
able between siblings and BD1 patients. Thus, even though
levels of traumatic stress or major life events were compar-
able, differences were present in the endocrine and auto-
nomic stress response in BD1 patients compared to healthy
controls and siblings, respectively. Moreover, adding trau-
matic stress scores or major life events as a covariate did
not change any of the results.
Previous studies have reported increased basal cortisol
levels in healthy offspring of BD1 patients (Ostiguy et al.,
2011), indicating that a genetic predisposition for BD1 may
result in alterations in HPA axis functionality. However, we
found no indication of changes in stress-induced cortisol and
alpha-amylase levels in unaffected siblings of BD1 patients.Therefore, this study supports and extends an earlier study in
which young offspring (age 13–21) displayed a similar cortisol
stress response compared to healthy controls (Ellenbogen
et al., 2006). In light of these data, an intermediate stress
reactivity phenotype in unaffected siblings of BD1 patients is
not likely.
Our ﬁndings should be interpreted in light of the existing
data on HPA-axis activity in bipolar disorder. Several studies in
which the HPA-axis was pharmacologically challenged showed
that there is a reduced negative feedback in bipolar disorder
patients, associated with hypercortisolism (Watson et al., 2004;
Rush et al., 1996; Rybakowski and Twardowska, 1999; Schmider
et al., 1995). This disrupted feedback has further been related
to decreased glucocorticoid receptor (GR) sensitivity in bi
polar disorder (for review see (Spijker et al., 2011)). Reduced
negative feedback would be expected to result in elevated
basal cortisol levels and enhanced cortisol response after stress.
Since we did not use any HPA-axis related pharmacological
intervention, our data can only indirectly assess feedback and
GR sensitivity. Nevertheless, from our data there is no
indication for a reduced negative feedback in patients with
bipolar disorder, as basal cortisol levels were unaffected and
there was an overall blunted cortisol stress response. A
possible explanation for the blunted cortisol stress response
is chronic exposure to increased cortisol levels that gradually
decrease the dynamic capacity of the HPA-axis. However,
conﬁrmation of this hypothesis would require prospective
follow-up of a population with a high-risk for developing
bipolar disorder. Importantly, antipsychotic use explained the
variation in cortisol stress reactivity in our study to a large
extent. This suggests that antipsychotic use rather than
bipolar disorder per se may be involved in a gradual blunting
of the cortisol response. Finally, in bipolar offspring, basal
cortisol levels but not stress-induced cortisol levels were
altered (Ellenbogen et al., 2006), indicating that these
cortisol measures cannot be compared directly.
The results of the present study should be interpreted in
the context of several potential limitations. First, as a result
of the cross-sectional nature of our study, we cannot deter-
mine the order of adaptation of the endocrine or autonomic
system. A second limitation is that this study was not
speciﬁcally set up to compare the effects of antipsychotic
use in a BD1 population. It is possible that more severely ill
and treatment-resistant BD1 patients were included who – as
a result – used increased doses of antipsychotic drugs.
However, antipsychotic use did not signiﬁcantly correlate
with clinical characteristics such as age of onset, comorbid
psychiatric diagnosis, and number of mood episodes. Third,
alpha-amylase was included as a measure for autonomic
stress reactivity whereas heart rate is a more common
readout parameter. Nevertheless, alpha-amylase is a vali-
dated autonomic stress marker which consistently correlates
to autonomic stress responses and noradrenaline release
(Nater and Rohleder, 2009; Rohleder et al., 2004). Unfortu-
nately, unaffected and unrelated siblings were more difﬁcult
to recruit, particularly as a result of daytime jobs, resulting in
a smaller sample size compared to the other groups, a
signiﬁcant higher number of female participants and a
signiﬁcant higher age. Although we adjusted for this we
cannot rule out residual confounding (Miller and Chapman,
2001). Strengths of the current study are the relatively large
overall sample size, the inclusion of unaffected siblings to
83Antipsychotic use s associated with a blunted cortisol stress responseinvestigate a possible genotype effects, inclusion of both
male and female participants, and assessment of current and
lifetime diagnosis.
In conclusion, the current study shows a blunted cortisol
stress response and increased autonomic stress response in
euthymic BD1 patients. Our data indicate that antipsychotic
use but not genetic loading is the most important determi-
nant of the blunted cortisol stress response in BD1 patients.
Even though it remains to be determined whether anti-
psychotics exert a protective or detrimental role in stress-
related processes in BD1 patients, our ﬁndings underscore
the possible importance of antipsychotic use on endocrine
stress reactivity.
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